

**REMARKS**

Favorable reconsideration and allowance of the claims of the present application are respectfully requested.

Applicants have carefully considered the Office Action mailed on November 25, 2009. Claims 22 and 38 are pending. Claim 22 is indicated as containing allowable subject matter. The Official Action has rejected Claim 38 under 35 U.S.C. §102(b) as allegedly anticipated by Hrabetova et al., (*Journal of Neuroscience*, 16(17):5324-5333, September 1, 1996.) (hereinafter, "Hrabetova").

Applicants would like to thank Examiner MacFarlane for speaking with Applicants' representative on February 17, 2010. During the interview proposed amendments to Claim 38 were discussed. No agreement was reached. Examiner MacFarlane suggested amending Claim 22 to recite a purified antibody  $\zeta$ -C2 raised against the sequence set forth in SEQ ID NO:2.

Applicants have amended Claim 22 to recite a purified antibody  $\zeta$ -C2 raised against the sequence set forth in SEQ ID NO:2, based on the suggestion of Examiner MacFarlane.

Applicants have canceled Claims 1-9, 12, 14-16, 18-21 and 24-38 without prejudice. Applicants reserve the right to re-file the subject matter of 1-9, 12, 14-16, 18-21 and 24-38 in continuation or divisional applications.

This Response addresses each of the Examiner's rejections. Applicants therefore respectfully submit that the present application is in condition for allowance.

**Rejections under 35 U.S.C. §102**

Claim 38 stands rejected under 35 U.S.C. §102(b) as allegedly anticipated by Hrabetova. Claim 38 has been canceled without prejudice, rendering this rejection moot.

In view of the foregoing amendments and remarks, it is firmly believed that the subject application is in condition for allowance, which action is earnestly solicited.

Respectfully submitted,



Peter I. Bernstein  
Registration No. 43,497

Scully, Scott, Murphy & Presser, P.C.  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343  
PIB/DRB:vh